个体化可变剂量与固定剂量全身糖皮质激素治疗慢阻肺急性加重住院患者的比较:前瞻性、多中心、随机、开放标签临床试验
这项前瞻性、多中心、随机、开放标签试验将248例慢阻肺急性加重住院患者按1:1随机分为固定剂量组(等效泼尼松龙40 mg)和个体化剂量组,治疗5天。主要终点为包含院内治疗失败和出院后中期失败的复合指标。个体化剂量组治疗失败率为27.6%,显著低于固定剂量组的48.8%(相对风险0.40;95%CI 0.24-0.68;
要点
- 个体化剂量糖皮质激素较固定40 mg可显著降低慢阻肺急性加重住院患者的治疗失败风险。
- 个体化剂量组院内治疗失败率显著更低,中期失败率、不良事件、住院时间和费用两组相似。
核心结论
- 个体化剂量糖皮质激素可降低慢阻肺急性加重住院患者的治疗失败风险,因更多患者接受了更高的初始剂量(尤其是>60 mg),而≤40 mg在两组中均过低。
研究设计与样本
- 前瞻性、多中心、随机、开放标签临床试验,248例慢阻肺急性加重住院患者按1:1随机分为固定剂量组(n=124)和个体化剂量组(n=124),治疗5天。
- 每组各有1例因初始慢阻肺诊断不正确而未纳入意向治疗人群。
主要发现
- 中期失败率、不良事件率、住院时间和费用两组相似。
- 治疗失败后,个体化剂量组需要更低的额外糖皮质激素剂量和更短的治疗持续时间来控制急性加重。
关键数值与推荐
- 固定剂量组接受等效泼尼松龙40 mg,个体化剂量组根据剂量量表给药,疗程均为5天。
- 主要终点为包含院内治疗失败和出院后中期失败的复合指标。
临床怎么用
- 对慢阻肺急性加重住院患者,可考虑根据剂量量表给予个体化糖皮质激素剂量,而非固定40 mg。
- 初始剂量不宜≤40 mg等效泼尼松龙,更多患者可能需要>60 mg的初始剂量。
- 个体化剂量可在不增加不良事件、住院时间或费用的情况下降低治疗失败风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic corticosteroids for the treatment of COPD exacerbations decrease treatment failure and shorten the length of hospitalization. However, the optimal dose is unclear. RESEARCH QUESTION: Is personalized-dose corticosteroid administered according to a dosing scale more effective than fixed-dose corticosteroid administration in hospitalized patients with COPD with exacerbations? STUDY DESIGN AND METHODS: This was a prospective, randomized, open-label trial. In-hospital patients with COPD with exacerbations were randomly assigned at a 1:1 ratio to either the fixed-dose group (receiving the equivalent of 40 mg of prednisolone) or the personalized-dose group for 5 days. The primary end point was a composite measure of treatment failure that included in-hospital treatment failure and medium-term (postdischarge) failure. Secondary end points were length of stay and cost. RESULTS: A total of 248 patients were randomly assigned to the fixed-dose group (n = 124) or personalized-dose group (n = 124). One patient in each group was not included in the intention-to-treat population because of incorrect initial COPD diagnosis. Failure of therapy occurred in 27.6% in the personalized-dose group, compared with 48.8% in the fixed-dose group (relative risk, 0.40; 95% CI, 0.24-0.68; P = .001). The in-hospital failure of therapy was significantly lower in the personalized-dose group (10.6% vs 24.4%; P = .005), whereas the medium-term failure rate, adverse event rate, hospital length of stay, and costs were similar between the two groups. After treatment failure, a lower additional dose of corticosteroids and a shorter duration of treatment were needed in the personalized-dose group to achieve control of the exacerbation. In the personalized-dose cohort, those receiving 40 mg or less had an average failure rate of 44.4%, compared with 22.9% among those receiving more than 40 mg (P = .027). INTERPRETATION: Personalized dosing of corticosteroids reduces the risk of failure because more patients were provided with a higher initial dose, especially > 60 mg, whereas 40 mg or less was too low in either group. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02147015; URL: www.clinicaltrials.gov.
引用
- Li L, Zhao N, Ma X, et al. Personalized Variable vs Fixed-Dose Systemic Corticosteroid Therapy in Hospitalized Patients With Acute Exacerbations of COPD: A Prospective, Multicenter, Randomized, Open-Label Clinical Trial. Chest. 2021. PMID: 34023318. doi:10.1016/j.chest.2021.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。